The Transatlantic Trade and Investment Partnership (TTIP) aims to create more open trade between the EU and the U.S. Strengthening the world’s most important trading relationship can serve as a key platform to bring quicker new treatment options to patients. TTIP has the potential to facilitate the development of new medicines and improve health outcomes and support new long-term economic benefits.
The innovative pharmaceutical industry supports a comprehensive and ambitious agreement that promotes regulatory compatibility, strengthens intellectual property protection, and enhances patient access to innovative medicines. Moreover, increased regulatory compatibility can, for example, be expected to have a particularly positive impact on smaller companies and collaborations that are central to the broader life sciences ecosystem. EFPIA strongly believes that a strong TTIP agreement can help accelerate global development of medicines and enhance patient access to much-needed innovative medicines.